Who is sponsoring NCT00076375?

NCT00076375 is sponsored by Nucryst Pharmaceuticals.

What drugs are being tested in NCT00076375?

Interventions in NCT00076375: Nanocrystalline silver cream (NPI).

What condition does NCT00076375 study?

NCT00076375 studies Atopic Dermatitis, Eczema.

Is NCT00076375 still recruiting?

NCT00076375 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00076375

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis

Completed Phase 2 Last updated 23 June 2005

What this trial tests

Phase 2 trial testing Nanocrystalline silver cream (NPI) in Atopic Dermatitis in 180 participants. Completed in 1 April 2004.

Timeline

1 November 2003

1 April 2004

Quick facts

Lead sponsor	Nucryst Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	180
Start date	1 November 2003
Estimated completion	1 April 2004
Sites	19 locations across United States

Drugs / interventions tested

Nanocrystalline silver cream (NPI) — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →
Eczema — all drugs for Eczema →

Sponsor

Nucryst Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, any sex, with Atopic Dermatitis or Eczema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nanocrystalline silver (very small particles of silver) is the active ingredient in Acticoat dressings, which have been approved for the treatment of burns and other wounds. Silver has been used for decades as an effective antimicrobial agent. In animal studies, nanocrystalline silver cream (NPI) has also demonstrated anti-inflammatory activity. Thus, nanocrystalline silver cream is being evaluated in the treatment of inflammatory skin conditions such as atopic dermatitis (eczema). Approximately 180 study subjects with a definitive diagnosis of mild to moderate eczema will be enrolled in this study. Subjects will be randomly assigned to treatment with placebo, 0.5% NPI or 1% NPI for the 6-week treatment period. Assessments of treatment effect and safety will be performed weekly. Upon completion of the study, subjects may be eligible for 12 weeks of open-label treatment with 1% NPI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers.
Vyas J, Raytthatha N, Vyas P, Singh S, et al · · 2026 · PMID 41639533 · DOI 10.1007/s13659-025-00585-w

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00076375 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nucryst Pharmaceuticals
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00076375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing